2013_top_10_papers_in _mycology_icaac_für_mykosen-online

Top 10 Papers in Mycology

Brown GD, Denning DW, Gow NAR, Levitz S, Netea MG, White TC. Hidden
kil ers: Human fungal infections. Sci Transl Med 19 Dec 2012; 4, 165rv13
Lewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli
P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP. Mycoses. Epidemiology and
sites of involvement of invasive fungal infections in patients with haematological
malignancies: a 20-year autopsy study. 2013 Apr 4. doi: 10.1111/myc.12081.
[Epub ahead of print]
1. Diagnostics

Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, Blanco M,
Demas V, Skewis LR, Anagnostou T, Coleman JJ, Wel man P, Mylonakis E,
Lowery TJ. T2 magnetic resonance enables nanoparticle-mediated rapid
detection of candidemia in whole blood. Sci Transl Med. 2013 Apr
24;5(182):182ra54.
Morrissey CO, Chen SC, Sorrel TC, Mil iken S, Bardy PG, Bradstock KF, Szer J,
Hal iday CL, Gilroy NM, Moore J, Schwarer AP, Guy S, Bajel A, Tramontana AR,
Spelman T, Slavin MA; Australasian Leukaemia Lymphoma Group and the
Australia and New Zealand Mycology Interest Group. Galactomannan and PCR
versus culture and histology for directing use of antifungal treatment for invasive
aspergil osis in high-risk haematology patients: a randomised control ed trial.
Lancet Infect Dis. 2013 Jun;13(6):519-28.
Mil on L, Larosa F, Lepil er Q, Legrand F, Rocchi S, Daguindau E, Scherer E,
Bel anger AP, Leroy J, Grenouil et F. Quantitative polymerase chain reaction
detection of circulating DNA in serum for early diagnosis of mucormycosis in
immunocompromised patients. Clin Infect Dis. 2013 May;56(10):e95-101.
2. Epidemiology & risk factors

Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, Etienne K,
Deak E, Derado G, Shieh WJ, Drew C, Zaki S, Sugerman D, Gade L, Thompson
EH, Sutton DA, Engelthaler DM, Schupp JM, Brandt ME, Harris JR, Lockhart SR,
Turabelidze G, Park BJ. Necrotizing cutaneous mucormycosis after a tornado in
Joplin, Missouri, in 2011. N Engl J Med. 2012 Dec 6;367(23):2214-25.
+ Comment on
Warkentien T, Rodriguez C, Lloyd B, Wel s J, Weintrob A, Dunne JR, Ganesan
A, Li P, Bradley W, Gaskins LJ, Seil ier-Moiseiwitsch F, Murray CK, Mil ar EV,
Keenan B, Paolino K, Fleming M, Hospenthal DR, Wortmann GW, Landrum ML,
Kortepeter MG, Tribble DR; Infectious Disease Clinical Research Program
Trauma Infectious Disease Outcomes Study Group.Invasive mold infections
fol owing combat-related injuries. Clin Infect Dis. Blood. 2013 Mar
28;121(13):2385-92.
+ Comment on
Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly
Rep. 2013 Mar 29;62(12):217-21. Increase in reported coccidioidomycosis--
United States, 1998-2011.
+ Comment on
Roy M, Benedict K, Deak E, Kirby MA, McNiel JT, Sickler CJ, Eckardt E, Marx
RK, Heffernan RT, Meece JK, Klein BS, Archer JR, Theurer J, Davis JP, Park
BJ. A large community outbreak of blastomycosis in Wisconsin with geographic
and ethnic clustering. Clin Infect Dis. 2013 Sep;57(5):655-62.
+ Comment on
Hagen F, Colom MF, Swinne D, Tintelnot K, Iatta R, Montagna MT, Torres-
Rodriguez JM, Cogliati M, Velegraki A, Burggraaf A, Kamermans A, Sweere JM,
Meis JF, Klaassen CH, Boekhout T. Autochthonous and dormant Cryptococcus
gatti infections in Europe. Emerg Infect Dis. 2012 Oct;18(10):1618-24.
3. Therapy for IFI: Cryptococcal meningitis
Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD,
Phong ND, Thai CQ, Thai le H, Chuong LV, Sinh DX, Duong VA, Hoang TN,
Diep PT, Campbel JI, Sieu TP, Baker SG, Chau NV, Hien TT, Lal oo DG, Farrar
JJ. Combination antifungal therapy for cryptococcal meningitis.N Engl J Med.
2013 Apr 4;368(14):1291-302
+ Comment on
Chen SC, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, Currie BJ,
Hajkowicz K, Heath CH, Kidd S, McBride WJ, Meyer W, Murray R, Playford EG,
Sorrel TC; for the Australia and New Zealand Mycoses Interest Group (ANZMIG)
Cryptococcus Study. Antifungal Therapy and Management of Complications of
Cryptococcosis due to Cryptococcus gattii. Clin Infect Dis. 2013 Jun 23. [ePub
ahead of print]
+ Comment on
Loyse A, Thangaraj H, Easterbrook P, Ford N, Roy M, Chil er T, Govender N,
Harrison TS, Bicanic T. Cryptococcal meningitis: improving access to essential
antifungal medicines in resource-poor countries. Lancet Infect Dis. 2013
Jul;13(7):629-3.
4. Exserohilum outbreak: controversies in clinical management
Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, Park BJ, Kanago ML, Baumblatt J, Schaefer MK, Berger BE, Marder EP, Min JY, Dunn JR, Smith RM, Dreyzehner J, Jones TF; Tennessee Fungal Meningitis Investigation Team. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012 Dec 6;367(23):2194-203. Malani AN, Vandenberg DM, Singal B, Kasotakis M, Koch S, Moudgal V, Jagarlamudi R, Neelakanta A, Otto MH, Halasyamani L, Kaakaji R, Kauffman CA. Magnetic resonance imaging screening to identify spinal and paraspinal infections associated with injections of contaminated methylprednisolone acetate. JAMA. 2013 Jun 19;309(23):2465-72. + comment on
Gade L, Scheel CM, Pham CD, Lindsley MD, Iqbal N, Cleveland AA, Whitney
AM, Lockhart SR, Brandt ME, Litvintseva AP. Detection of fungal DNA in human
body fluids and tissues during a multistate outbreak of fungal meningitis and
other infections. Eukaryot Cel . 2013 May;12(5):677-83.
+ comment on
Zhao Y, Petraitiene R, Walsh TJ, Perlin DS. A real-time PCR assay for rapid
detection and quantification of Exserohilum rostratum, a causative pathogen of
fungal meningitis associated with injection of contaminated methylprednisolone.
Clin Microbiol. 2013 Mar;51(3):1034-6.
5. Resistance
Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfal er MA , Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.Clin Infect Dis. 2013 Jun;56(12):1724-32. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, Karawajczyk A, Zoll J, Melchers WJ, Verweij PE Aspergil osis due to Voriconazole Highly Resistant Aspergil us fumigatus and Recovery of Genetical y Related Resistant Isolates From Domiciles. Clin Infect Dis. 2013 Aug;57(4):513-20. + comment on Lewis JS 2nd, Wiederhold NP, Wickes BL, Patterson TF, Jorgensen JH. Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother. 2013 Jul 1. [Epub ahead of print] + comment on Camps SM, Rijs AJ, Klaassen CH, Meis JF, O'Gorman CM, Dyer PS, Melchers
WJ, Verweij PE. Molecular epidemiology of Aspergil us fumigatus isolates
harboring the TR34/L98H azole resistance mechanism.J Clin Microbiol. 2012
Aug;50(8):2674-80.
+ comment on
Fraczek MF, Bromley M, Buied A, Moore CB, Rajendran R, Ranjith, Rautemaa
R, Ramage G, Denning DW, Bowyer P. The CDR1B efflux transporter is
associated with non-CYP51A mediated azole resistance in Aspergil us
fumigatus. J Antimicrob Chemother 2013;68:1486-96.
6. Drugs and toxicity

Gerber B, Guggenberger R, Fasler D, Nair G, Manz MG, Stussi G, Schanz U.
Reversible skeletal disease and high fluoride serum levels in hematologic
patients receiving voriconazole. .Blood. 2012 Sep 20;120(12):2390-4. Epub 2012
Aug 2.
+comment on
Zeuli JD, Wilson JW, Estes LL. .Effect of combined fluoroquinolone and azole
use on QT prolongation in hematology patients. Antimicrob Agents Chemother.
2013 Mar;57(3):1121-7
+comment on
Farmakiotis D, Tverdek FP, Kontoyiannis DP. The safety of amphotericin B lipid
complex in patients with prior severe intolerance to liposomal amphotericin B.
Clin Infect Dis. 2013 Mar;56(5):701-3
+ comment on
Boyd NK, Zoel ner CL, Swancutt MA, Bhavan KP. Utilization of omeprazole to
augment subtherapeutic voriconazole concentrations for treatment of Aspergil us
infections. Antimicrob Agents Chemother. 2012 Nov;56(11):6001-2.
7. Antifungal therapy for chronic and allergic disease
Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Itraconazole in chronic cavitary pulmonary aspergil osis: a randomised control ed trial and systematic review of literature. Mycoses. 2013 Sep;56(5):559-70 + comment on Al-Shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW.Long-term Antifungal Treatment Improves Health Status in Patients With Chronic Pulmonary Aspergil osis: A Longitudinal Analysis. Clin Infect Dis. 2013 Jul 18. (ePub ahead of print)

Source: http://www.mykosen-online.de/fileadmin/mykosen-online.de/media/Veranstaltungen/2013/2013_Top_10_papers_in__Mycology_ICAAC.pdf